• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Pergolide (marketed as Permax) - Overview

Listen to this Podcast 

Run Time — 00:01:44


Welcome to the Food and Drug Administration's drug safety update. I am Pat Clarke from F-D-A's Center for Drug Evaluation and Research.

On March 29, 2007, we issued a public health advisory about the voluntary Market Withdrawal of Permax, a drug to treat the symptoms of Parkinson's disease. The drug is also known and marketed by its generic name pergolide [per-go-lide].

The companies that manufacture and distribute pergolide have agreed to withdraw this drug from the market due to the potential for heart valve damage.

Patients who are taking pergolide and their health care provessionals should discuss other treatments for Parkinson's disease that are not associated with heart valve damage. You should not stop pergolide abruptly, because this can be dangerous.

To hear the full public health advisory, listen to Part 2 of this broadcast.

We are asking health-care professionals to report serious adverse events in connection with pergolide to us through the MedWatch program by phone at 1-800-F-D-A-ten-88 or by the Internet at F-D-A dot gov slash MedWatch.

To hear the full public health advisory, listen to part 2 of this broadcast. Updated information about drugs with emerging safety concerns is available 24 hours a day at our Web site W-W-W dot F-D-A dot gov slash C-D-E-R.



Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857